A Phase 2, Open-Label Study With Orally Administered CVM-1118 and Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Unknown Phase 2 NCT03582618

Study Description

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.

Study Details

Registry ID:: NCT03582618
Conditions:: Hepatocellular Carcinoma, Advanced Cancer
Phase:: Phase 2
Target Enrollment:: 12 participants
Start Date:: July 12, 2018
Healthy Volunteers:: No

Study Locations (3 sites)

Charleston Hematology Oncology Associates
Charleston, South CarolinaUnited States, United States
National Cheng Kung University Hospital
TainanTaiwan, Taiwan
National Taiwan University Hospital
TaipeiTaiwan, Taiwan

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →